申请人:SMITH KLINE & FRENCH LABORATORIES
LIMITED
公开号:EP0403199A3
公开(公告)日:1992-02-12
Polymers of structure:
in which,
R is hydrogen or
R¹ and R² are each C₁₋₄alkyl;
R³ is CONR⁴R⁵, NR⁴COR⁶, a phthalamido group, COR⁷ or OH;
R⁴ and R⁵ are the same or different and are each hydrogen or C₁₋₈alkyl;R⁶ is C₁₋₄alkyl, C₁₋₄alkylC₃₋₆cycloalkyl, CF₃ or NR⁴R⁵;
R⁷ is hydroxy, C₁₋₄alkyl or C₁₋₄alkoxy;
n is 2 to 12;
a, b and c are numbers which indicate the relative molar percentages of the units present in said polymer, (b) being from 1 to 10 molar percent, and (c) being from 30 to 98 molar percent;
X⊖ is a counter ion,
processes for their preparation, pharmaceutical compositions containing them and their use in therapy as cholesterol lowering agents.
结构聚合物:其中,R为氢或R¹和R²分别为C₁₋₄烷基;R³为CONR⁴R⁵,NR⁴COR⁶,邻苯二酰胺基团,COR⁷或OH;R⁴和R⁵相同或不同,分别为氢或C₁₋₈烷基;R⁶为C₁₋₄烷基,C₁₋₄烷基C₃₋₆环烷基,CF₃或NR⁴R⁵;R⁷为羟基,C₁₋₄烷基或C₁₋₄烷氧基;n为2至12;a、b和c为相对摩尔百分比指示的单体在所述聚合物中的相对摩尔百分比,其中(b)为1至10摩尔百分比,(c)为30至98摩尔百分比;X⊖为反离子,其制备方法,含有它们的制药组合物以及它们作为降低胆固醇的药物在治疗中的用途。